TGF-β1 inhibitor enhances the therapeutic effect of microwave ablation on hepatocellular carcinoma

References

• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1–11.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.
   PubMed Web of Science ®Google Scholar
• Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi: 10.1038/s41575-019-0186-y.
   PubMed Web of Science ®Google Scholar
• EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
   PubMed Web of Science ®Google Scholar
• Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;14(3):199–208. doi: 10.1038/nrc3672.
   PubMed Web of Science ®Google Scholar
• Liang P, Yu J, Yu X-L, et al. Percutaneous cooled-tip microwave ablation under ultrasound guidance for primary liver cancer: a multicentre analysis of 1363 treatment-naive lesions in 1007 patients in China. Gut. 2012;61(7):1100–1101. doi: 10.1136/gutjnl-2011-300975.
   PubMed Web of Science ®Google Scholar
• Zhang NN, et al. High-powered microwave ablation of larger hepatocellular carcinoma: evaluation of recurrence rate and factors related to recurrence. Clin Radiol. 2015;70(11):1237–1243.
   PubMed Web of Science ®Google Scholar
• Yu J, Liang P, Yu X-L, et al. Local tumour progression after ultrasound-guided microwave ablation of liver malignancies: risk factors analysis of 2529 tumours. Eur Radiol. 2015;25(4):1119–1126. doi: 10.1007/s00330-014-3483-4.
   PubMed Web of Science ®Google Scholar
• Teratani T, Yoshida H, Shiina S, et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology. 2006;43(5):1101–1108. doi: 10.1002/hep.21164.
   PubMed Web of Science ®Google Scholar
• Huang S, et al. Percutaneous microwave ablation for hepatocellular carcinoma adjacent to large vessels: a long-term follow-up. Eur J Radiol. 2014;83(3):552–558.
   PubMed Web of Science ®Google Scholar
• Ren H, et al. Treatment of liver tumours adjacent to hepatic hilum with percutaneous microwave ablation combined with ethanol injection: a pilot study. Int J Hyperthermia. 2011;27(3):249–254.
   PubMed Web of Science ®Google Scholar
• El Dika I, Makki I, Abou-Alfa GK. Hepatocellular carcinoma, novel therapies on the horizon. Chin Clin Oncol. 2021;10(1):12–12. doi: 10.21037/cco-20-113.
   PubMed Web of Science ®Google Scholar
• Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14(4):203–217. doi: 10.1038/nrgastro.2016.193.
   PubMed Web of Science ®Google Scholar
• Singal AG, Nehra M, Adams-Huet B, et al. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol. 2013;108(3):425–432. doi: 10.1038/ajg.2012.449.
   PubMed Web of Science ®Google Scholar
• Kalogeridi MA, et al. Role of radiotherapy in the management of hepatocellular carcinoma: a systematic review. World J Hepatol. 2015;7(1):101–112.
   PubMedGoogle Scholar
• Rinninella E, Cerrito L, Spinelli I, et al. Chemotherapy for hepatocellular carcinoma: current evidence and future perspectives. J Clin Transl Hepatol. 2017;5(3):235–248.
   PubMedGoogle Scholar
• Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267–296.
   PubMed Web of Science ®Google Scholar
• Machlenkin A, Goldberger O, Tirosh B, et al. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity. Clin Cancer Res. 2005;11(13):4955–4961. doi: 10.1158/1078-0432.CCR-04-2422.
   PubMed Web of Science ®Google Scholar
• Duan X, Wang M, Han X, et al. Combined use of microwave ablation and cell immunotherapy induces nonspecific immunity of hepatocellular carcinoma model mice. Cell Cycle. 2020;19(24):3595–3607. doi: 10.1080/15384101.2020.1853942.
   PubMed Web of Science ®Google Scholar
• Li X, Zhang Q, Lu Q, et al. Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: a single-arm, preliminary study. Front Immunol. 2022;13:1023983. doi: 10.3389/fimmu.2022.1023983.
   PubMed Web of Science ®Google Scholar
• Dituri F, Mancarella S, Cigliano A, et al. TGF-β as multifaceted orchestrator in HCC progression: signaling, EMT, immune micro­environment, and novel therapeutic perspectives. Semin Liver Dis. 2019;39(1):53–69. doi: 10.1055/s-0038-1676121.
   PubMed Web of Science ®Google Scholar
• Larson C, Oronsky B, Carter CA, et al. TGF-beta: a master immune regulator. Expert Opin Ther Targets. 2020;24(5):427–438.
   PubMed Web of Science ®Google Scholar
• van den Bulk J, de Miranda N, Ten Dijke P. Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression. Clin Sci (Lond). 2021;135(1):35–52. doi: 10.1042/CS20201236.
   PubMed Web of Science ®Google Scholar
• de Streel G, Lucas S. Targeting immunosuppression by TGF-β1 for cancer immunotherapy. Biochem Pharmacol. 2021;192:114697.
   PubMed Web of Science ®Google Scholar
• Wang B, Liu T, Wu JC, et al. STAT3 aggravates TGF-β1-induced hepatic epithelial-to-mesenchymal transition and migration. Biomed Pharmacother. 2018;98:214–221.
   PubMed Web of Science ®Google Scholar
• Sun H, Huang Q, Huang M, et al. Human CD96 correlates to natural killer cell exhaustion and predicts the prognosis of human hepatocellular carcinoma. Hepatology. 2019;70(1):168–183. doi: 10.1002/hep.30347.
   PubMed Web of Science ®Google Scholar
• Jin X, Zhang S, Wang N, et al. High expression of TGF-β1 contributes to hepatocellular carcinoma prognosis via regulating tumor immunity. Front Oncol. 2022;12:861601. doi: 10.3389/fonc.2022.861601.
   PubMed Web of Science ®Google Scholar
• Luo Y, Huang K, Zheng J, et al. TGF-β1 promotes cell migration in hepatocellular carcinoma by suppressing reelin expression. Gene. 2019;688:19–25. doi: 10.1016/j.gene.2018.11.033.
   PubMed Web of Science ®Google Scholar
• Huang J, Qiu M, Wan L, et al. TGF-β1 promotes hepatocellular carcinoma invasion and metastasis via ERK pathway-mediated FGFR4 expression. Cell Physiol Biochem. 2018;45(4):1690–1699. doi: 10.1159/000487737.
   PubMedGoogle Scholar
• Sun SL, Wang XY. TGF-β1 promotes proliferation and invasion of hepatocellular carcinoma cell line HepG2 by activating GLI-1 signaling. Eur Rev Med Pharmacol Sci. 2018;22(22):7688–7695.
   PubMed Web of Science ®Google Scholar
• Tu J, Zhao Z, Xu M, et al. NEAT1 upregulates TGF-β1 to induce hepatocellular carcinoma progression by sponging hsa-mir-139-5p. J Cell Physiol. 2018;233(11):8578–8587.
   PubMed Web of Science ®Google Scholar
• Wegner K, Bachmann A, Schad JU, et al. Dynamics and feedback loops in the transforming growth factor β signaling pathway. Biophys Chem. 2012;162:22–34.
   PubMed Web of Science ®Google Scholar
• Heo J-Y, Do J-Y, Lho Y, et al. TGF-β1 receptor inhibitor SB525334 attenuates the epithelial to mesenchymal transition of peritoneal mesothelial cells via the TGF-β1 signaling pathway. Biomedicines. 2021;9(7):839. doi: 10.3390/biomedicines9070839.
   PubMed Web of Science ®Google Scholar
• Roth GS, Decaens T. Liver immunotolerance and hepatocellular carcinoma: patho-physiological mechanisms and therapeutic perspectives. Eur J Cancer. 2017;87:101–112.
   PubMed Web of Science ®Google Scholar
• Mao X, Xu J, Wang W, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131. doi: 10.1186/s12943-021-01428-1.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lazarus J, Steele NG, et al. Regulatory T-cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis. Cancer Discov. 2020;10(3):422–439. doi: 10.1158/2159-8290.CD-19-0958.
   PubMed Web of Science ®Google Scholar
• Batlle E, Massagué J. Transforming growth factor-β signaling in immunity and cancer. Immunity. 2019;50(4):924–940. doi: 10.1016/j.immuni.2019.03.024.
   PubMed Web of Science ®Google Scholar
• Stuelten CH, Zhang YE. Transforming growth factor-β: an agent of change in the tumor microenvironment. Front Cell Dev Biol. 2021;9:764727. doi: 10.3389/fcell.2021.764727.
   PubMed Web of Science ®Google Scholar
• Zhang H, Hou X, Cai H, et al. Effects of microwave ablation on T-cell subsets and cytokines of patients with hepatocellular carcinoma. Minim Invasive Ther Allied Technol. 2017;26(4):207–211.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Xu X, Ding J, et al. Dynamic changes of T-cell subsets and their relation with tumor recurrence after microwave ablation in patients with hepatocellular carcinoma. J Cancer Res Ther. 2018;14(1):40–45. doi: 10.4103/jcrt.JCRT_775_17.
   PubMed Web of Science ®Google Scholar
• Huang S, Li T, Chen Y, et al. Microwave ablation combined with anti-PD-1 therapy enhances systemic antitumor immunity in a multitumor murine model of Hepa1-6. Int J Hyperthermia. 2022;39(1):278–286.
   PubMed Web of Science ®Google Scholar
• Budhu S, Schaer DA, Li Y, et al. Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. Sci Signal. 2017;10(494):10. doi: 10.1126/scisignal.aak9702.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu T, Tang W, et al. Hepatocellular carcinoma cells induce regulatory T cells and lead to poor prognosis via production of transforming growth factor-β1. Cell Physiol Biochem. 2016;38(1):306–318. doi: 10.1159/000438631.
   PubMed Web of Science ®Google Scholar
• Fezza M, Moussa M, Aoun R, et al. DKK1 promotes hepatocellular carcinoma inflammation, migration and invasion: implication of TGF-β1. PLoS One. 2019;14(9):e0223252. doi: 10.1371/journal.pone.0223252.
   PubMed Web of Science ®Google Scholar
• Du Y, Liu X, Du K, et al. Decorin inhibits the formation of hard nodules after microwave ablation by inhibiting the TGF-β1/SMAD and MAPK signaling pathways: in a bama miniature pig model of mammary gland hyperplasia. Int J Hyperthermia. 2023;40(1):2188151.
   PubMed Web of Science ®Google Scholar
• Chen L, Wang M, Lin Z, et al. Mild microwave ablation combined with HSP90 and TGF‑β1 inhibitors enhances the therapeutic effect on osteosarcoma. Mol Med Rep. 2020;22(2):906–914. doi: 10.3892/mmr.2020.11173.
   PubMed Web of Science ®Google Scholar
• Chen J, Gingold JA, Su X. Immunomodulatory TGF-β signaling in hepatocellular carcinoma. Trends Mol Med. 2019;25(11):1010–1023.
   PubMed Web of Science ®Google Scholar